(NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today ...

The 'Beverly Hills, 90210' star died at age 52 in March 2019, just days after suffering a massive stroke — but his legacy ...

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpointsPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today ...

Nearly 13.8 percent of stroke patients in India are below 45 years, with hypertension identified as the leading risk factor ...

Transient Ischemic Attack, also known as "mini-stroke", occurs when there is a temporary blockage of blood flow to the brain. The American Stroke Association says that the clot usually dissolves on ...

Heart Symptoms Common in Seniors Without Cardiac Disease Older adults with no diagnosis of cardiac disease often experience heart-related symptoms such as fatigue, exertional shortness of breath, and ...

For many stroke survivors, recovery is derailed by painful muscle stiffness and involuntary spasms that limit movement, independence, and quality of life. Often viewed as an unavoidable consequence of ...

A popular "natural" sugar substitute found in thousands of diet foods and drinks may be damaging the brain's protective barrier and increasing stroke risk, according to research from the University of ...

Stroke is a global challenge, affecting more than 13 million people each year. The majority of stroke patients are left with permanent disabilities that undermine their independence, and create a ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...

Fact checked by Nick Blackmer Magnesium is a mineral essential for many bodily processes, including healthy muscle and nerve ...

Bristol Myers Squibb today announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study (NCT05664737) evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in ...